Vivos Therapeutics (VVOS) Other financing activities (2023 - 2026)

Vivos Therapeutics (VVOS) has reported Other financing activities for 3 consecutive years, with -$447000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to -$447000.0 in Q2 2026; TTM through Jun 2026 was $4.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.7 million, down 77.35% from the prior year.
• Other financing activities was -$447000.0 for Q2 2026 at Vivos Therapeutics, down from $4.6 million in the prior quarter.
• Over five years, Other financing activities peaked at $8.0 million in Q1 2023 and troughed at -$447000.0 in Q2 2026.
• A 3-year average of $3.9 million and a median of $3.9 million in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 12.5% in 2024, down 50.74% in 2024.
• Over 3 years, Other financing activities stood at $4.0 million in 2023, then declined by 12.5% to $3.5 million in 2024, then sank by 112.77% to -$447000.0 in 2026.
• The last three Other financing activities figures came in at -$447000.0 (Q2 2026), $4.6 million (Q1 2026), and $3.5 million (Q4 2024), per Business Quant data.